Vesugen
Also known as: Vezugen, KED peptide, Lys-Glu-Asp, T-38, tripeptide T-38
Short regulatory tripeptide / cytogen / geroprotector
What it is
Vesugen is a short peptide studied for vascular protection, anti-aging, and skin regeneration, with research suggesting it supports gene activity in blood vessel and nerve cells. It works by influencing gene expression in target tissues to maintain or restore function. No FDA-approved use; primarily studied in Russian longevity research.
The scientific side
Vesugen (Lys-Glu-Asp; KED) is a short tripeptide that appears to exert its biological effects primarily through epigenetic and transcriptional regulation. Studies report that it interacts with promoter regions of target genes (including MKI67, the gene encoding Ki-67, and the 5-tryptophan hydroxylase gene) via molecular docking complementarity, modulating gene expression at nanomolar concentrations. Reported molecular effects include: stimulation of proliferation-associated Ki-67 expression and inhibition of proapoptotic p53 in vascular endothelial and other cells; normalization of endothelin-1 expression and restoration of connexin-mediated cell interactions in endothelium; upregulation of sirtuin-1 involved in DNA repair; stimulation of IGF1 gene expression and inhibition of FOXO1 in mesenchymal stem cells; tissue-specific induction of differentiation markers CXCL12 and WEGC1 in prostatic fibroblasts; stimulation of serotonin synthesis in brain cortex cells; and inhibition of MMP-9 while enhancing Ki-67 and CD98hc in aging skin fibroblasts. In neurons and induced neurons, KED promotes dendritic arborization and reduces oxidative DNA damage. The peptide also demonstrated anti-atherosclerotic molecular activity by reducing E-selectin synthesis and normalizing endothelin-1 in vascular cells.
Class: Short regulatory tripeptide / cytogen / geroprotector
Administration & storage
- Administration
- Intraperitoneal injection — used in animal study of pancreatic function (PMID: 18942368)Oral administration — reported for KED in elderly humans with functional CNS disorders (PMID: 34173097)
- Storage
- No storage conditions for Vesugen are described in any of the reviewed abstracts.
- Cautions
- Prooxidant activity was detected via chemiluminescence in a human study of Vesugen and Pinealon as geroprotectors.,Decrease of CD34+ positive hematopoietic polypotent cells in blood was observed, suggesting significant inhibition of hemopoiesis in the study population.,No effect on chromatin condensation was observed, interpreted by the authors as safety at the nuclear genetic level, though the authors noted this property should be studied further.,Human pharmacokinetic data (absorption, distribution, metabolism, excretion) are not reported in any reviewed abstract — clinical safety profile is incompletely characterized.,Sterile technique is essential for any injectable preparation to prevent contamination.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Geroprotection / biological age reduction Human observational
- In 110 subjects across age groups, combined use of Vezugen and Pinealon oligopeptide complexes produced the most pronounced positive impact on biological age indicators among the geroprotective techniques compared. Oligopeptide drugs were among the safest interventions evaluated. PMID 28539017 Myakotnykh et al., Advances in gerontology (2016)
- In 32 patients (aged 41–83) with polymorbidity and organic brain syndrome, Vesugen demonstrated significant anabolic effect and more visible geroprotective effect than Pinealon by biological age indicators. Prooxidant activity detected via chemiluminescence; no effect on chromatin condensation (considered safe at nucle PMID 26390612 Meshchaninov et al., Advances in gerontology (2015)
- Combined application of peptide geroprotectors (cytogens) restored and enhanced adaptive resources and corrected work ability index in occupational hazard workers subjected to accelerated aging. PMID 28509489 Bashkireva & Kachan, Advances in gerontology (2015)
- Vasoprotection / atherosclerosis and vascular endothelial function Mixed
- KED peptide normalized endothelin-1 expression (elevated in atherosclerosis and restenosis), restored connexin-mediated cell interactions, and increased sirtuin-1 expression in normal, atherosclerotic, and restenotic endothelium in vitro. PMID 28539025 Kozlov et al., Advances in gerontology (2016)
- Vesugen and D-7 stimulated Ki-67 expression in tissue-specific vascular endothelial cell cultures from young and old animals. Molecular docking showed vesugen interacts with the MKI67 gene promoter, suggesting epigenetic regulation of Ki-67 expression as a mechanism of vasoprotective effect. PMID 25051766 Khavinson et al., Bulletin of experimental biology and medicine (2014)
- In 41 patients with vasculogenic erectile dysfunction as a manifestation of atherosclerosis, Vezugen monotherapy significantly improved blood flow through main penile arteries by both clinical and objective (Doppler) indicators. PMID 25051774 Kitachev et al., Advances in gerontology (2014)
- Neuroprotection and neurogenesis support Mixed
- KED (and EDR, AEDG) peptides promoted arborization of the dendritic tree (increased primary processes and total dendrite length) in fibroblast-derived induced neurons from elderly donors. EDR reduced oxidative DNA damage; KED had no significant effect on mitochondrial/lysosomal activity or p16 level in this model. PMID 39518916 Kraskovskaya et al., International journal of molecular sciences (2024)
- Oral application of KED improved memory and attention in elderly individuals with functional CNS disorders. KED restored synaptic plasticity in an in vitro model of Alzheimer's disease and regulated expression of genes involved in apoptosis (p16, p21), neuronal differentiation (NES, GAP43), and AD pathogenesis (SUMO, A PMID 34173097 Khavinson et al., Bulletin of experimental biology and medicine (2021)
- Lys-Glu-Asp stimulated serotonin expression in aging cultures of brain cortex cells. Molecular docking demonstrated complementarity between KED and the CCTGCC sequence in the 5-tryptophan hydroxylase gene, suggesting epigenetic regulation of serotonin synthesis. PMID 24909721 Khavinson et al., Bulletin of experimental biology and medicine (2014)
- KED alone and a compound of KED+AED+AEDG+KE peptides increased expression of GAP43 and Nestin in human periodontal ligament stem cells, promoting neuronal differentiation. PMID 30791821 Caputi et al., International journal of immunopathology and pharmacology (2019)
- Skin fibroblast regeneration and anti-aging effects In vitro only
- KED (along with KE, AED, AEDG) inhibited MMP-9 synthesis (which increases during aging) and enhanced Ki-67 and CD98hc expression (which decrease during aging) in skin fibroblasts in culture. PMID 27259496 Lin'kova et al., Bulletin of experimental biology and medicine (2016)
- Vesugen (Lys-Glu-Asp) tissue-specifically stimulated expression of differentiation factors CXCL12 and WEGC1 in aging cultures of human prostatic fibroblasts; effect was more pronounced in aged cultures. PMID 22808515 Khavinson et al., Bulletin of experimental biology and medicine (2012)
- Mesenchymal stem cell gene expression modulation In vitro only
- The short peptides AED, KED and KE together enhanced IGF1 gene expression 3.5–5.6 fold at nanomolar concentrations (the abstract does not separate KED's share); KED inhibited FOXO1 gene expression (1.6–2.3 fold), modulated TNKS2 expression (model-dependent direction), and stimulated NFκB gene expression in aging human PMID 32399807 Ashapkin et al., Molecular biology reports (2020)
- Antihypoxic / neuroprotective effects in hypoxia models Animal studies only
- Short regulatory peptides including vesugen manifested antihypoxic properties in a model of hypobaric hypoxia in rats, though pinealon had the most pronounced effect among the peptides tested. PMID 18546825 Kozina, Advances in gerontology (2008)
- Pancreatic function restoration in accelerated aging models Animal studies only
- Administration of tripeptide T-38 (Lys-Glu-Asp) to old irradiated rats activated post-irradiation reparative regeneration and restored disordered endocrine homeostasis in the pancreas. Route: intraperitoneal injection. PMID 18942368 Ryzhak et al., Advances in gerontology (2008)
- Pineal gland immune cell proliferation In vitro only
- Tripeptide vesugen had no effect on differentiation capacity of immune cells in pineal gland organotypic culture but enhanced their proliferation potential. PMID 22803057 Linkova et al., Bulletin of experimental biology and medicine (2011)
- Lys-Glu-Asp stimulated Ki-67 expression in pineal gland organotypic culture from 3-month-old rats but did not affect AIF (apoptosis marker) expression. PMID 22803060 Khavinson et al., Bulletin of experimental biology and medicine (2011)
- Lymphoid tissue / splenic cytoprotection Animal studies only
- Tripeptide T-38 (Lys-Glu-Asp) at 0.05 ng/ml produced a stimulatory effect on growth zone of splenic lymphoid tissue explants and, in the presence of cyclophosphamide, prevented cytostatic-induced inhibition of cell proliferation in both young and old rats. PMID 19110568 Chalisova et al., Bulletin of experimental biology and medicine (2008)
- Neuroimmunoendocrine system cell modulation Animal studies only
- Tripeptide Lys-Glu-Asp stimulated proliferation and inhibited apoptosis in organotypic cultures of neuroimmunoendocrine system cells (pineal gland, immune cells). Effect on nervous and endocrine tissues was more pronounced in cultures from old animals. Also modulated associative learning in honey bee models of short- a PMID 22977872 Chalisova et al., Bulletin of experimental biology and medicine (2012)
- Psychoemotional / neurobehavioral correction in occupational stress Human observational
- Combined application of cytogens pinealon and vezugen in lorry-drivers restored organism adaptive potential, improved psychoemotional indices, intensified stress resistance, and reduced occupational risk of borderline mental disorders (p < 0.001–0.05). Best effect was obtained from combined application. PMID 23734521 Bashkireva & Artamonova, Advances in gerontology (2012)
- Lipid peroxidation restriction and red blood cell membrane stabilization (in vitro) In vitro only
- Vesugen (along with pinealon, vilon, epitalon) did not demonstrate direct antioxidant activity but restricted lipid peroxidation of human lipoproteins by modifying their structure and increased stability of red blood cell membranes toward osmotic hemolysis in vitro. Vesugen (along with vilon and pinealon, but not epita PMID 18546826 Kozina et al., Advances in gerontology (2008)
Safety signals
- Prooxidant activity detected via chemiluminescence in a human study of Vesugen and Pinealon as geroprotectors in patients with organic brain syndrome. PMID 26390612
- Significant decrease in CD34+ hematopoietic polypotent cells in blood, indicating inhibition of hemopoiesis, observed in human patients receiving Vesugen and Pinealon. PMID 26390612
- No effect on chromatin condensation was observed; authors considered the peptides safe at the nuclear genetic level but noted further study is needed. PMID 26390612
Protocol
100 mcg subcutaneous injection, once daily. Cycle: 10 days.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| In vitro (organotypic culture) | 0.05 ng/ml (in culture medium) | Not specified in abstract | in_vitro | Research PMID 19110568 |
| In vitro (cell culture) | Nanomolar concentrations (exact value not specified in abstract) | Not specified in abstract | in_vitro | Research PMID 32399807 |
| subcutaneous injection | 100 mcg | once daily · 10 days | biohackers and longevity-focused adults interested in cardiovascular and vascular health | [Community] |
| subcutaneous injection | 100 mcg | once daily · 20 days | biohackers and longevity-focused adults with more pronounced vascular concerns or seeking deeper intervention | [Community] |
| subcutaneous injection | 200 mcg | once daily · 10 days | biohackers experimenting with higher-dose bioregulator peptide protocols | [Community] |
| oral (capsule/tablet — peptide bioregulator form) | 10 mg | once daily · 30 days | longevity-focused biohackers preferring oral bioregulator peptide products (e.g., Vladonix-class oral tablets) | [Community] |
| oral (capsule/tablet — peptide bioregulator form) | 10 mg | once daily · 60 days | older adults (50+) and longevity biohackers using oral bioregulator stacks for systemic anti-aging | [Community] |
All studies (21)
- PMID 23734521 Human observational
Psychoemotional / neurobehavioral correction in occupational stress - PMID 26390612 Human observational
Geroprotection / biological age reduction - PMID 28509489 Human observational
Geroprotection / biological age reduction - PMID 28539017 Human observational
Geroprotection / biological age reduction - PMID 24909721 Mixed
Neuroprotection and neurogenesis support - PMID 25051766 Mixed
Vasoprotection / atherosclerosis and vascular endothelial function - PMID 25051774 Mixed
Vasoprotection / atherosclerosis and vascular endothelial function - PMID 28539025 Mixed
Vasoprotection / atherosclerosis and vascular endothelial function - PMID 30791821 Mixed
Neuroprotection and neurogenesis support - PMID 34173097 Mixed
Neuroprotection and neurogenesis support - PMID 39518916 Mixed
Neuroprotection and neurogenesis support - PMID 18546825 Animal studies only
Antihypoxic / neuroprotective effects in hypoxia models - PMID 18546826 In vitro only
Lipid peroxidation restriction and red blood cell membrane stabilization (in vitro) - PMID 18942368 Animal studies only
Pancreatic function restoration in accelerated aging models - PMID 19110568 Animal studies only
Lymphoid tissue / splenic cytoprotection - PMID 22803057 In vitro only
Pineal gland immune cell proliferation - PMID 22803060 In vitro only
Pineal gland immune cell proliferation - PMID 22808515 In vitro only
Skin fibroblast regeneration and anti-aging effects - PMID 22977872 Animal studies only
Neuroimmunoendocrine system cell modulation - PMID 27259496 In vitro only
Skin fibroblast regeneration and anti-aging effects - PMID 32399807 In vitro only
Mesenchymal stem cell gene expression modulation
Frequently asked
What is Vesugen and what is it used for?
Vesugen (also called Vezugen or KED, the tripeptide Lys-Glu-Asp) is a short regulatory peptide studied primarily for geroprotective (anti-aging), vasoprotective, and neuroprotective effects. Published studies report uses including: improvement of biological age indicators in humans (PMID 28539017, PMID 26390612); improvement of blood flow in vasculogenic erectile dysfunction; normalization of vascular endothelial markers in atherosclerosis models; stimulation of neuronal differentiation and dendritic growth (PMID 39518916, PMID 30791821); and modulation of aging-related gene expression in stem cells. Most mechanistic data come from in vitro or animal studies; human clinical data are limited.
What dose of Vesugen should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: human studies of Vesugen do not report specific doses in the available abstracts (PMID 26390612, PMID 25051774, PMID 34173097). In vitro animal studies used concentrations such as 0.05 ng/ml in organotypic culture and nanomolar concentrations in stem cell cultures, but these are laboratory values and cannot be translated directly to human dosing.
How is Vesugen administered — oral or injectable?
Published abstracts report two routes: oral administration was mentioned in a review of KED use in elderly humans with functional CNS disorders, and intraperitoneal injection was used in an animal study of pancreatic function. Human clinical studies did not specify route or dose in sufficient detail in the available abstracts. I can't recommend an administration route for you specifically — please consult a licensed healthcare provider.
Is Vesugen safe? Are there any side effects?
Safety data from reviewed abstracts are limited. In a human study (n=32, aged 41–83), Vesugen and Pinealon were associated with prooxidant activity detected by chemiluminescence and a significant decrease in CD34+ hematopoietic cells (suggesting hemopoiesis inhibition). No effect on chromatin condensation was observed, which the authors interpreted as safety at the nuclear genetic level, though they noted further study is warranted. No formal contraindications were reported in any reviewed abstract. Human pharmacokinetic data are absent from the reviewed literature. Please consult a licensed healthcare provider for a complete safety assessment.
Can Vesugen help with Alzheimer's disease or dementia?
Preclinical and in vitro evidence suggests KED (Lys-Glu-Asp) may have neuroprotective properties relevant to Alzheimer's disease: it restored synaptic plasticity in an in vitro AD model, regulated expression of AD-relevant genes (APOE, SUMO, IGF1), and improved memory/attention in elderly individuals with functional CNS disorders in one review. KED and related peptides also promoted dendritic arborization in aging-model neurons and neuronal differentiation markers in stem cells. However, no controlled human clinical trials in Alzheimer's disease patients are reported in the reviewed abstracts. I can't suggest treatments for medical conditions — please speak with a licensed healthcare provider.
What is the mechanism of action of Vesugen?
Based on the reviewed literature, Vesugen (Lys-Glu-Asp) appears to act primarily through epigenetic regulation of gene expression. Studies report: molecular docking-demonstrated interaction with the promoter region of the MKI67 gene (Ki-67) in vascular endothelial cells; complementarity with the CCTGCC sequence of the 5-tryptophan hydroxylase gene, suggesting regulation of serotonin synthesis; normalization of endothelin-1 and upregulation of sirtuin-1 in vascular endothelium; and stimulation of IGF1 and inhibition of FOXO1 in mesenchymal stem cells at nanomolar concentrations. Tissue-specific induction of differentiation markers has also been reported.
Can I stack Vesugen with other peptides like Pinealon?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Several human observational studies used Vesugen and Pinealon together, reporting improved biological age indicators, anabolic and neuroprotective effects, and improved psychoemotional outcomes in occupational stress. However, combined use was also associated with prooxidant activity and hemopoiesis inhibition signals. Individual compound safety profiles are incompletely characterized in the available literature.
Where can I buy Vesugen?
I don't recommend vendors or sources. Please consult a licensed provider.
Does Vesugen have any effect on testosterone or sexual function?
One clinical study (n=41 male patients) reported that Vezugen monotherapy significantly improved blood flow in main penile arteries in patients with vasculogenic erectile dysfunction related to atherosclerosis, by both clinical and objective Doppler measures. No data on testosterone levels or other hormonal effects were reported in the reviewed abstracts. I don't have reliable study data on testosterone specifically — please consult a licensed provider or peer-reviewed literature directly.
Is Vesugen approved by the FDA or other regulatory agencies?
The reviewed published abstracts do not state the regulatory status of Vesugen with any regulatory agency (FDA, Health Canada, WADA, or others). This requires manual verification with the relevant regulatory authorities. Please consult a licensed healthcare provider or check official regulatory databases.